GlassScriptPhysician profile
Julia K Wood
NPI 1245435825
$6,498.44
in general payments reported to CMS, 2019-2025
31 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $308 · 2021: $504 · 2022: $911 · 2023: $1,109 · 2024: $977 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,354 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.79 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $738.88 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $631.03 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $564.92 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $486.90 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $451.17 | 2019-2025 | Trintellix |
| Abbvie INC. | $425.62 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $391.03 | 2020-2025 | Caplyta |
| Alkermes, INC. | $334.35 | 2019-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $323.42 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $255.33 | 2019-2022 | |
| Allergan, INC. | $188.93 | 2019-2020 | |
| Neos Therapeutics, LP | $161.85 | 2024-2025 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $159.08 | 2020-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $153.99 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $147.88 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $145.85 | 2023-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $139.16 | 2019-2024 | Aplenzin |
| Corium, LLC | $118.72 | 2022-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $110.81 | 2023-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $103.23 | 2022-2023 | Qelbree |
| Almatica Pharma LLC | $90.06 | 2021-2024 | Loreev Xr |
| Acadia Pharmaceuticals INC | $66.62 | 2024-2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $66.42 | 2024-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $51.05 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $49.07 | 2023 | |
| Arbor Pharmaceuticals, INC. | $41.69 | 2019 | |
| Eisai INC. | $29.90 | 2021 | |
| Shire North American Group INC | $25.29 | 2019 | |
| Merck Sharp & Dohme LLC | $17.34 | 2023 | Belsomra |
| Adlon Therapeutics L.P. | $16.04 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.